Comprehensive Approaches to OAB in the Elderly with Comorbidities

Title:

Comprehensive Approaches to OAB in the Elderly with Comorbidities

Topic: Urology
Relevant Terms: Urology, general practice, internal medicine, obstetrics-gynecology
Primary Audience: Urologists, urogynecologists, obstetrician-gynecologists, primary care physicians, nurse practitioners, physician assistants, nurses
Launch Date: 31-May-17
Credits: 0.5 AMA PRA Category 1 Credit
0.5 ANCC contact hour
0.5 CPD contact hour
Expiration Date: 30-May-18
Curriculum Name: Case Clinic: Taking a More Aggressive Approach for Treatment of Persistent OAB Symptoms

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Evaluate overactive bladder (OAB), particularly in the presence of comorbidities, considering the impact on quality of life
  2. Inform patients about current and emerging therapeutic options and strategies for managing OAB, focusing on the patient's needs and assessing efficacy, tolerability, and optimal adherence
  3. Engage in more effective provider-patient dialogues to identify the patient's needs and improve outcomes for OAB
  4. Provide proper counseling and support to patients with OAB to increase their motivation for treatment-plan adherence and to improve patient quality of life               

    Faculty

    Martin Wehling, MD
    Professor of Clinical Pharmacology
    University of Heidelberg
    Mannheim, Germany
    Program Description
    Comorbidities and polypharmacy are often common in older individuals who present with overactive bladder (OAB); patients may need to be screened for other possible causes of urinary urgency. First-line therapy for OAB is always lifestyle interventions. Second–line treatments include antimuscarinics or a beta-3 adrenergic agent. Moreover, a combination of changes in lifestyle with drug therapy may be more effective than either treatment on its own in older individuals. This case report describes in detail treatment selection, and the adjustments that often must be considered and implemented, in an older patient with OAB who presents with multiple comorbidities.
     
    Provided by Global Education Group in collaboration With Haymarket Medical Education.
     
    Supported by an educational grant from Astellas.
     
    Faculty Information
    Martin Wehling, MD
    Professor of Clinical Pharmacology
    University of Heidelberg 
    Mannheim, Germany
     
    Faculty Disclosures
    Martin Wehling, MD, is a consultant for and on the speakers bureau for Pfizer.
     
    Publishing Staff Disclosures
    Susan Basilico, Angie Ladas, and Nick Zittell have nothing to disclose.
     
    Accreditation Statement(s)
    Physician Credit: Global Education Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      
    Nursing Credit: Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
     
    Credit Designation Statement(s)
    Physician Credit Designation: Global Education Group designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Nursing Credit Designation: This educational activity for 0.50 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Astellas or Global Education Group. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. If you have any questions relating to the accreditation of this activity, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com 
     
    Method of Participation Instructions
    To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. 
     
    Privacy Policy
    http://www.mycme.com/privacypolicy/
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.